Bill Newman: As Argentina Backpedals, Will Oil and Gas Companies Step on the Gas?
Source: Peter Byrne of The Energy Report  (8/6/13)
Argentina's nationalist seizure of YPF's assets last year stunned markets, but loss of foreign investment compromised the nation's energy self sufficiency. Now, says Bill Newman of Mackie Research, the government is taking steps in the right direction. In this interview with The Energy Report, Newman outlines the political landscape and identifies promising plays in the region. More >

Finding Bargains Down Under with Rick Rule
Source: Karen Roche of The Gold Report  (8/5/13)
Down markets are notoriously rife with good deals, and nowhere is this truer than Down Under. In this interview with The Gold Report, Rick Rule, founder of Sprott Global Resource Investments, explains how he takes advantage of Australia's small, volatile market and investors' ethnocentrism to find high-quality companies whose shares are, in his opinion, going for a steal. More >

What's Behind July's 9% Rise in Crude Oil Prices
Source: Tony Daltorio, Money Morning  (8/5/13)
"U.S. crude oil prices finished the month of July on a very positive note. Front-month futures ended July at just above $105 a barrel. That put those futures up about 9% for July, the largest one-month gain for crude oil in 11 months." More >

Believe It or Not: Gold's 8-Year Cycle Still on Track
Source: Mary Anne and Pamela Aden, The Aden Forecast  (8/2/13)
"Gold's movements are in line with historic trends, never mind what the no-nothing, hand-wringing Cassandra's are saying." More >

Our Worry-Free Way of Investing in Biotech
Source: Greg Madison, Money Morning  (8/2/13)
"We are on the cusp of some truly amazing discoveries. There is a tier of biotech companies working around the clock on products with amazing potential." More >

Off to the Races with Seven Extraordinary Biotech and Medtech Companies: Jason Napodano
Source: George S. Mack of The Life Sciences Report  (8/1/13)
Senior Biotechnology Analyst Jason Napodano of Zacks Investment Research specializes in uncovering small biotech and medtech companies with good prospects for successful drug development. He relishes proven management capable of creative financing to move private equity into the public markets, and he does not shy away from tiny companies outside the U.S. that have extraordinary technology. In this wide-ranging interview with The Life Sciences Report, Napodano presents the elegant growth stories of seven small companies that could return magnificent gains to investors. More >

Six Oncology-Focused Biotech Growth Engines: Mara Goldstein
Source: George S. Mack of The Life Sciences Report  (8/1/13)
For Cantor Fitzgerald Senior Biotechnology Analyst Mara Goldstein, the spotlight is always on oncology and the premium revenues commanded by new products in the space. That clarity brings the science, unmet needs and market opportunity into sharp focus for investors. In this interview with The Life Sciences Report, Goldstein makes a winning case for six cancer-focused companies that range from micro caps to genuine large-cap stocks, each with upside potential that could be stunning. More >

Top Ten Stocks for a Uranium Price Rebound: David Talbot
Source: Zig Lambo of The Energy Report  (8/1/13)
When it comes to uranium market sentiment, "it's all about Japan," says David Talbot, senior mining analyst at Dundee Capital Markets. With restart applications trickling in and reactor construction underway throughout the world, a turnaround looks less like an "if" and more like a "when." In the meantime, Talbot sees many investors sitting on the sidelines. In this interview with The Energy Report, Talbot discusses the catalysts that could trigger the next uranium boom and the companies that could make investors wish they had arrived at the party a little earlier. More >

Counterpoint: Supply and Demand in the Rare-Earths Market 2015–2020
Source: Jack Lifton, Technology Metals Research  (8/1/13)
"In the rare-earth total supply chain, China is most of the global ball game." More >

Chris Berry's Strategies for Profiting from a Distorted Reality: Investing After QE
Source: J. Alec Gimurtu of The Gold Report  (7/31/13)
Quantitative easing has created new problems for commodity investors—the systemic distortion of true supply-demand for commodities. What is a long-term investor to do? In this interview with The Gold Report, Chris Berry, founder of Mountain House Partners, explains what specific factors make a compelling junior miner in this market and lays out his strategy for profiting from a QE-distorted reality. More >

Gold Nears 10% Monthly Gain
Source: Adrian Ash, BullionVault  (7/31/13)
"The relationship between the gold price and real U.S. interest rates, adjusted for inflation, is less clear." More >

Jocelyn August: Top Five Catalysts for Small-Cap Energy Equities
Source: Brian Sylvester of The Energy Report  (7/30/13)
Catalysts are a little like earthquakes: They shake things up. These announcements of drill results, production starts and resource estimates can influence stock prices, sometimes for the better, sometimes for the worse. In this interview with The Energy Report, Jocelyn August, senior analyst and product manager for Sagient Research's CatalystTracker, explains which catalysts have the biggest effect on small- and large-cap companies and identifies upcoming events that could move the needle in the oil and gas and uranium spaces. More >

Chris Berry: Rare Earth Stocks Show Signs of Life, but Will the Uptrend Stick?
Source: Alec Gimurtu of The Metals Report  (7/30/13)
Prices for rare earths and some rare earth mining stocks are showing positive price action following China's crackdown on illegal mines. But is this the beginning of a sustained recovery, or just a temporary blip on the screen? House Mountain Partners founder Chris Berry explores these questions in this interview with The Metals Report and shares his macroeconomic outlook. As Berry reminds us, V-shaped recoveries are preferred, but rare. That means investors must cultivate patience and courage. More >

Ron Struthers: Are Gold Equities on the Cusp of an Upswing?
Source: Brian Sylvester of The Gold Report  (7/29/13)
It is like a carrot on a stick for small-cap mining investors: the promise that we have finally hit bottom and prices will rise again for gold and mining stocks. That time is almost here, according to Ron Struthers, the publisher and editor of Struthers' Resource Stock Report. In this interview with The Gold Report, Struthers discusses how a run on bullion banks has played with the gold price and which indicator is telling him things are about to move. If Struthers' forecast is right, the gold market could be on the cusp of one of its best corrections yet.
More >

Now Is the Time to Build New Mines, But It Ain't That Easy
Source: Lawrence Williams, Mineweb  (7/29/13)
"Financial analysis suggest now is the ideal to start work on mega mining projects before price cycles turn up again, but this is easier said than done." More >

Profit from Palladium's Bullish Trend
Source: Sean Brodrick, ETF Daily News  (7/29/13)
"I call palladium the Rodney Dangerfield of metals because it 'gets no respect, I tell ya, no respect at all.'" More >

Is It Time to Start to Talk About Geothermal Again?
Source: Jason Hamlin, Gold Stock Bull  (7/29/13)
"Geothermal is a renewable energy source that is expected to grow fivefold in the next seven years and produces more than double the energy of solar and wind combined." More >

How to Invest in LNG: A 3-Step Strategy
Source: Keith Schaefer, Oil & Gas Investments Bulletin  (7/26/13)
"Greg Coleman outlines his three-stage plan for grabbing a chunk of the profits from the massive ramp-up coming in LNG." More >

Meet High Risk and High Reward, Biotech's Profit Partners: Bert Hazlett
Source: George S. Mack of The Life Sciences Report  (7/25/13)
Small-cap biotech investing carries real risk. Startup companies tend to have only a few ideas in development, which leaves ample room for setbacks—even room for disaster. Robert "Bert" Hazlett, senior biotechnology research analyst with ROTH Capital Partners, doesn't mind taking such risks, but tempers them with a diversification strategy designed to minimize the impact of potential hiccups and blowups. In this interview with The Life Sciences Report,
Hazlett expands on his strategy and mentions four companies with experienced management teams and high hopes for huge returns.
More >

Mesoblast Ltd. Targets Success in the Degenerative Disc Space
Source: George S. Mack of The Life Sciences Report  (7/25/13)
The biggest challenge in the treatment of degenerative disc disease lies in the inhospitable nature of the intervertebral space, where the blood flow and nutrients necessary to cell survival are in short supply. Mesoblast Ltd. has developed a cell therapy that addresses that challenge, triggering the regenerative qualities of surrounding cells to promote healing. In this interview with The Life Sciences Report, Mesoblast Founder, CEO and Managing Director Silviu Itescu describes the science that promises relief to millions of back pain sufferers. More >

BioRestorative Therapies Inc. Develops Plug-and-Play Therapy for Bulging/Herniated Disc Disease
Source: George S. Mack of The Life Sciences Report  (7/25/13)

Millions of people suffer back pain caused by herniated and bulging disc disease. When conventional medical therapies fail they often resort to surgery for relief, a costly and time-consuming solution for both patients and the medical system. In this interview with The Life Sciences Report, Mark Weinreb, president, CEO and chairman of BioRestorative Therapies Inc., describes how his company's cell therapy process could keep disc disease treatment out of the operating theater.

Is Cell Therapy the 'Future of Medicine'?: Jason Kolbert
Source: George S. Mack of The Life Sciences Report  (7/25/13)
The pricey evolutionary tradeoff for walking on two legs is the curse of lower back pain. Jason Kolbert of the Maxim Group understands the power of stem cells as disease-modifying therapies for degenerative disc disease of the spine, a leading-edge, multibillion-dollar indication. Kolbert explores the opportunities that cell therapies offer investors in this interview with The Life Sciences Report, and puts a personal spin on their regenerative promise. More >

Capture Upside in Undervalued, Underfollowed Energy Stocks: Peter Epstein
Source: Rita Sapunor of The Energy Report  (7/25/13)
Big gains are rarely found by jumping on the bandwagon. Peter Epstein, independent analyst and founder of MockingJay Inc., argues that market darlings won't reward latecomers; that's why he spends his time finding undervalued, underfollowed junior resource companies. In this interview with The Energy Report, Epstein shares his resource stock diamonds in the rough, including a uranium name commercializing a groundbreaking technology and a graphite company beating its competitors to market. More >

U.S. Global Investors' Secret: 'Keep Calm and Invest On'
Source: Brian Sylvester of The Gold Report  (7/24/13)
As an investor, you probably get a lot of advice and don't know which to follow: There are conflicting reports, Fed announcements, figures that tell only half the story. In this interview with The Gold Report, Ralph Aldis, senior mining analyst with U.S. Global Investors, helps investors parse these many information streams, explains what seasonal gold pricing patterns could mean for investors and offers a stable of junior equities that could provide greater leverage to a gold price recovery. More >

Why Gold Mining Stocks Are a Buy Now
Source: Gary Gately, Money Morning  (7/24/13)
"You have to choose carefully when picking gold mining stocks or ETFs to buy." More >